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The effects of 4 mg·kg−1caffeine ingestion on strength and power were investigated 
for the first time, in resistance-trained females during the early follicular phase utiliz-
ing a randomized, double-blind, placebo-controlled, crossover design. Fifteen females 
(29.8 ± 4.0 years, 63.8 ± 5.5 kg [mean ± SD]) ingested caffeine or placebo 60 min-
utes before completing a test battery separated by 72 hours. One-repetition maximum 
(1RM), repetitions to failure (RTF) at 60% of 1RM, was assessed in the squat and 
bench press. Maximal voluntary contraction torque (MVC) and rate of force devel-
opment (RFD) were measured during isometric knee extensions, while utilizing in-
terpolated twitch technique to measure voluntary muscle activation. Maximal power 
and jump height were assessed during countermovement jumps (CMJ). Caffeine me-
tabolites were measured in plasma. Adverse effects were registered after each trial. 
Caffeine significantly improved squat (4.5 ± 1.9%, effect size [ES]: 0.25) and bench 
press 1RM (3.3 ± 1.4%, ES: 0.20), and squat (15.9 ± 17.9%, ES: 0.31) and bench 
press RTF (9.8 ± 13.6%, ES: 0.31), compared to placebo. MVC torque (4.6 ± 7.3%, 
ES: 0.26), CMJ height (7.6 ± 4.0%, ES: 0.50), and power (3.8 ± 2.2%, ES: 0.24) were 
also significantly increased with caffeine. There were no differences in RFD or mus-
cle activation. Plasma [caffeine] was significantly increased throughout the protocol, 
and mild side effects of caffeine were experienced by only 3 participants. This study 
demonstrated that 4 mg·kg−1 caffeine ingestion enhanced maximal strength, power, 
and muscular endurance in resistance-trained and caffeine-habituated females dur-
ing the early follicular phase, with few adverse effects. Female strength and power 
athletes may consider using this dose pre-competition and -training as an effective 
ergogenic aid.
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1 |  INTRODUCTION
Caffeine (1,3,7-trimethylxanthine) is the most widely used 
legal drug in the world, by the general as well as athletic pop-
ulations,1 and researchers’ interest in the effects of caffeine 
on exercise performance is apparent in light of multiple re-
views of the literature published in the recent years.2-5 These 
reviews currently agree that caffeine is a potent ergogenic aid 
for a variety of exercise performances; however, the effects of 
caffeine on maximal strength and power performance are less 
clear. Meta-analyses by Warren et al6 and Polito et al7 showed 
that caffeine ingestion can increase isometric strength and 
muscular endurance performance. However, Polito et al7 
could not observe improved dynamic strength with caffeine 
supplementation, and a recent meta-analysis by Grgic et al4 
only found increased performance in upper but not lower 
body dynamic strength. On the other hand, increased mus-
cular endurance has been demonstrated with larger effect 
sizes in lower body rather than upper body exercises.7 The 
conflicting results could be due to varying effect of caffeine 
on different types of contractions, as the contribution of cor-
tical and spinal centers to the neural drive changes with the 
contraction type.8 Hence, further research is warranted to in-
vestigate the effect of caffeine on maximal isometric versus 
dynamic strength, power, and muscular endurance, as well as 
comparing lower and upper body muscle groups.
A recent review of the caffeine literature found that only 
~13% of the total sample in research on the ergogenic effect 
of caffeine between 1978 and 2018 were women and that 
the number of women in studies investigating caffeine ef-
fects on speed and muscle power is very low.9 A likely ex-
planation for this difference in representation of the sexes 
is that females can be a slightly more challenging cohort 
to conduct caffeine research on. The use of oral contracep-
tives10 and the large variations in hormone concentrations 
between phases of the menstrual cycles11 can alter caffeine 
metabolization speeds,12 which in turn may alter the ergo-
genic effects of caffeine. Indeed, significant sex differences 
have been reported in caffeine concentrations post-exercise 
with ingestion of 3 mg/kg caffeine, with females having a 
greater amount. This suggests that females do not metab-
olize caffeine as rapidly as males. Furthermore, variations 
in strength and power have been demonstrated through-
out the menstrual cycle,13 which can cause noise in per-
formance data and affect overall results. Taken together, 
although there are a number of studies demonstrating that 
caffeine clearly has an ergogenic effect in females,9,14-16 the 
information about the effect of caffeine on muscle perfor-
mance in women is uncertain, especially in strength and 
power performance. As an example, a recent meta-sub-
group analysis examined the effects of caffeine on muscle 
power in females for the first time.4 However, only three 
studies examining vertical jumps were included and neither 
controlled for potential metabolic alterations across the 
menstrual cycle, making it difficult to conclude on the ef-
fects of caffeine on power in females. Moreover, a recent 
study found differences in the effect of caffeine on power 
performance between the phases in the menstrual cycle.17 
It, therefore, seems important to control for stages in the 
menstrual cycle to further establish clear recommendations 
for the use of caffeine in females. The early follicular phase 
of the menstrual cycle has shown the lowest variability in 
oestradiol and progesterone concentration,18 and the sex 
hormone levels in this phase are similar to the levels in 
females using hormone contraceptives.19 Furthermore, a 
recent study found that the fluctuations in sex hormones 
throughout the menstrual cycle affect neuromuscular func-
tion.20 Hence, conducting caffeine research on females 
would benefit from being performed at the same stage of 
the menstrual cycle and can reliably be performed during 
the early follicular phase.
The underlying mechanisms by which caffeine may aid 
maximal strength and power are likely increased motor unit 
recruitment and voluntary muscle activation of the involved 
muscles.6,21,22 However, there seem to be discrepancies in 
the caffeine effect on strength and power that corresponds 
to varying degree of baseline voluntary activation. Larger 
lower body muscles such as knee extensors seem to have a 
relatively low (85%-95%) muscle activation level compared 
to the small upper body muscles (90%-99%),6 such as elbow 
flexors.23 These differences in baseline muscle activation 
may influence the magnitude of the caffeine effect. As 
Warren et al6 discuss in their meta-analysis, logically there 
will be more to improve with lower baseline muscle activa-
tion levels, that is, larger lower body muscles might have 
a greater effect of caffeine. Correspondingly, strength and 
power improvements with caffeine have been reported in 
this pattern.6 However, one study in females shows the quite 
opposite pattern, that is, caffeine-induced improvements of 
upper body but not lower body maximal strength, although 
this needs further investigation.16 Perceived pain and exer-
tion during exhaustive resistance work have been thought 
to be reduced, and thereby improving performance, through 
caffeine's inhibitory binding to adenosine receptors.21 
However, caffeine's effect on intra-set ratings of perceived 
exertion seems under-investigated compared to post-fatigue 
ratings, although Doherty et al's meta-analysis24 observed 
that a ~5% reduction in intra-set ratings of perceived ex-
ertion (RPE) explained about a third of the variance in 
exhaustive work between caffeine and placebo. Moreover, 
the contribution of muscle activation to increased strength 
and power, comparison of upper and lower body maximal 
strength and effects on RPE and pain has to the authors’ 
knowledge, not been investigated specifically with moder-
ate caffeine doses in resistance-trained females while con-
trolling for menstrual cycle.
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Only three studies have investigated the effects of caf-
feine doses <6  mg·kg−1 on strength performance in fe-
males.16,25,26 Goldstein et al27 and others4 have specifically 
proposed that future research should examine the ergogenic 
effects of lower doses of caffeine. Several studies have 
reported severe side effects such as “intense emotional 
responses,” tremor, heart palpitations, and tachycardia 
when supplementing with relatively high doses of caffeine 
(6-11  mg·kg−1).27-29 A lower caffeine dose could induce 
similar performance enhancements but with fewer adverse 
events, which would be an advantage, especially to compet-
ing strength and power athletes.
Thus, the main purpose of the present study was to in-
vestigate, for the first time, the effects of 4 mg·kg−1 caffeine 
on various strength and power measures in resistance-trained 
females during the early follicular phase. We hypothesized 
a caffeine-induced increase in maximal strength and muscu-
lar activation levels, vertical jump height, as well as in mus-
cular endurance, compared to placebo ingestion. Secondary 
outcomes of the study were intra-set ratings of perceived 
exertion, perceived pain, plasma caffeine concentration, ha-
bituation, and adverse effects.
2 |  METHODS
2.1 | Participants
Fifteen caucasian female volunteers (age: 29.8 ± 5.5 years; 
stature: 165.8  ±  4.8  cm; body mass: 63.8  ±  5.5  kg 
[mean ± SD]) completed this study (Table 1). Nine of the 
25 recruited participants dropped out after randomization due 
to logistical issues, and one was excluded due to intake of a 
source of caffeine unknown to participant and researchers. 
Resistance-trained participants (recreational lifters, personal 
trainers, and functional fitness athletes) were recruited fol-
lowing these inclusion criteria: (a) 18-45 years old; (b) resist-
ance-trained for minimum 12 months, 2-3 sessions/week and 
currently resistance training; (c) ability to perform squat and 
bench press with a load corresponding to 110% and 80% of 
their current body mass, respectively, and (d) familiar with 
the bench press and back squat exercises (performed at least 
one time/wk). Participants were excluded if they were smok-
ers, pregnant, or lactating, were adversely affected by caf-
feine, used medicines and/or other ergogenic supplements, 
had history of recent injury, illness or other diseases that 
could affect measurements. Participants signed a written in-
formed consent and completed a Physical Activity Readiness 
Questionnaire (PAR-Q). Ethical approval was obtained from 
the research ethics committee of London Sports Institute, 
Middlesex University (London, UK) and the Norwegian 
School of Sport Science (Oslo, Norway). The project was ap-
proved by the Norwegian Centre for Research Data.
2.2 | Study design
A randomized, double-blind, placebo-controlled crossover 
design was used to investigate the effects of 4 mg·kg−1 caf-
feine on strength and power performance. The participants 
attended four sessions; two familiarizations to all procedures 
(except blood sampling) and to the test battery, and two tri-
als. However, three familiarization sessions were performed 
when the variation between the two first familiarization ses-
sions exceeded a coefficient of variation (CV) of 10% (total 
number of participants completing three familiarizations for 
one of the tests, n = 8). Participants were instructed to re-
frain from alcohol, caffeine, and vigorous physical activity 
48 hours prior to the trials and were provided with a detailed 
list of items containing caffeine, such as coffee, chocolate, 
tea, soda, and energy drinks. All participants recorded their 
weekly intake of these products using a caffeine frequency 
questionnaire to calculate their habitual caffeine intake 
(Table 1), and were classified as low, medium, or high caf-
feine consumers based on habitual intakes (<1.5, 1.5-5.0 and 
>5.0 mg·kg−1·d−1, respectively).30 They also completed a 24-
hour food diary (MyFitnessPal®, MyFitnessPal, Inc) prior to 
the first trial and replicated the food intake prior to the second 
trial to ensure minimal variation in hydration level and en-
ergy intake. Body composition was assessed by bioelectrical 
T A B L E  1  Participant characteristics.
Mean ± SD Range
Fat-free mass (kg)a 52.3 ± 5.2 44.4-63.2
Fat mass (kg)a 11.3 ± 4.0 4.9-21.2
Fat mass (%)a 17.7 ± 5.8 8.1-32.3
Hormone contraceptive use (n - %) 10 66.7
RE experience (y) 7 ± 5 2-16
RE frequency (sessions·wk−1) 4 ± 1 2-5
Squat 1RM (kg)b 97 ± 13 75-115
Squat 1RM (kg·bw−1) 1.5 ± 0.2 1.2-1.8
Bench press 1RM (kg)b 66 ± 10 50-82
Bench press 1RM (kg·bw−1) 1.0 ± 0.2 0.8-1.3
Energy (kcal)c 2208 ± 509 1473-
3497
Protein (g·d−1)c 143 ± 37 67-210
Carbohydrate (g·d−1)c 209 ± 54 130-301
Fat (g·d−1)c 84 ± 39 40-182
Caffeine (mg·d−1)d 341 ± 184 54-692
Note: Range: min-max.
Abbreviations: 1RM, one-repetition maximum; RE, resistance exercise.
aMeasured with InBody720. 
bBased on the maximal 1RM across the two familiarizations. 
cMean habitual intakes from a 24-h food diary prior to each test day. 
dHabitual caffeine intake questionnaire. 
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impedance analysis (InBody 720, InBody Co., Ltd) follow-
ing (a) 24  hours without vigorous exercise, (b) minimum 
2 hours fasting, and (c) emptying the bladder.
Both trials were performed at the same time of day, ap-
proximately 1  week after familiarization. The participants 
performed the caffeine and placebo trials at individually 
standardized test times, which was self-selected to corre-
spond with the participant's habitual training schedule. The 
trials were interspersed by 72 hours to ensure treatment wash-
out, allow for recovery and for both trials to be completed 
within the early follicular phase of the menstruation cycle 
as previously used by Chen et al15 This is when the concen-
tration and variation in estrogen and progesterone are low-
est as compared to other the phases of the menstrual cycle.18 
Participants using hormone contraceptives were included, as 
these show very similar levels of estrogen and progesterone 
to the levels during the early follicular phase.19 Confirmation 
of a new menstruation cycle was obtained from each partici-
pant prior to confirming trial day 1.
2.3 | Experimental protocol
All participants performed the test battery in the same order 
each day within the set amount of time of 210 minutes, in-
cluding rest intervals and breaks, estimated from pilot testing 
(Figure 1). Upon arrival, participants provided a urine sample 
for visual assessment of hydration status (The Urine Colour 
Chart®, Human Hydration, LLC). If the urine color chart in-
dicated a score of 5 or below, the participants were provided 
250-500 mL of water to improve hydration levels prior to con-
tinuing the protocol. In addition, 4 mL blood was collected 
from the cubital fossa veins (Vacuette® Multiple use draw-
ing needle; Vacuette® tube, 4 mL K2EDTA, Greiner Bio-One 
GmbH). Blood was further collected at 60 and 270 minutes 
following treatment ingestion. Subsequently, height and body 
mass were measured (SECA stadiometer, Model 213; SECA 
weight scale 876, respectively). All participants received a 
standardized meal 45 minutes prior to testing, consisting of 
0.4  g·kg−1 whey protein powder (0.36  g·kg−1 protein) and 
1.5 g·kg−1 banana (0.35 g·kg−1 carbohydrate). All participants 
performed a standardized warm-up for 10 minutes by cycling 
on a stationary bicycle at ~100 W at 80-90 RPM (Monark, 
Ergomedic 828E), followed by a standardized 5 minutes rest, 
and were equally verbally encouraged to perform to the best 
of their abilities during all tests. The participants completed 
questionnaires about their preparation adherence, withdrawal 
symptoms, and the Brunel Mood score (BRUMS) 24-item 
questionnaire31 prior to the protocol and an end-of-trial ques-
tionnaire about adverse effects and blinding, where the par-
ticipants were asked to state if they believed they had received 
caffeine, placebo or were unsure, after completion of the test 
battery and final blood sampling.
2.4 | Supplementation
Treatment was given 60  minutes prior to testing, allowing 
peak plasma levels of caffeine to coincide with testing.1 The 
treatments were administered as 150  mL non-caloric Fun 
Light© cordial concentrate from an opaque bottle. To pre-
pare the caffeine treatment, 4  mg·kg−1 anhydrous caffeine 
(Caffeine, ReagentPlus®, Sigma-Aldrich) was dissolved in 
the cordial concentrate with heat to ensure complete disso-
lution of the caffeine. Both treatments were equal in color, 
taste, and volume due to not diluting the cordial. The drink 
was rapidly ingested immediately followed by another 150-
mL cordial from a separate cup to conceal any potential 
bitter taste and rinse the mouth of caffeine residues. An inde-
pendent researcher randomized treatment order, mixed, and 
administered the treatments and held the key to the randomi-
zation until the end of the study.
2.5 | Measurements
2.5.1 | Countermovement jump
Participants performed the countermovement jump (CMJ) 
to assess jump height (cm), maximal power (W) and 
F I G U R E  1  Experimental protocol 
timeline. Overview of the experimental 
protocol. In addition, urine was observed at 
arrival for visual hydration status estimation 
with the urine color chart. 1RM, one-
repetition maximum; BP, bench press; CMJ, 
countermovement jump; ITT, interpolated 
twitch technique; MVC, maximal voluntary 
isometric contraction; SQ, squat; RTF, 
repetitions to failure
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maximal force (N). Participants were instructed to stand 
on a force plate (FP4, HUR Labs OY, Hur AB) with hands 
kept on their hips with legs shoulder width apart while ex-
ecuting a maximal vertical jump, from an upright position 
to a self-selected depth immediately prior to jumping. To 
warm-up, three submaximal CMJ trials with approximately 
50%, 75%, and 90% intensity were performed with 1-min-
ute breaks. After another 2  minutes rest, maximal effort 
CMJ trials with 2  minutes rest between each trial were 
performed for at least 3 sets. If the third set resulted in 
an improved jump height compared to the second, the par-
ticipants were allowed to continue until a set resulted in a 
decline in performance. Jump height was determined as the 
center of mass displacement, calculated from take-off force 
development and force plate-measured body mass with the 
provided software (Force Platform Software Suite, Version 
2.6.51). The single best result was noted and used for sta-
tistical analysis. Test-retest measurements revealed a CV 
of 9.7%, 5%, and 6% for jump height, maximal power, and 
maximal force, respectively.
2.5.2 | Maximal isometric strength, 
muscular activation level, and RFD
Peak torque, muscular activation level, and RFD were 
measured by maximal voluntary isometric contractions 
(MVC) of the right knee extensor muscles, while seated 
in a knee extension machine (Knee extension, Gym2000; 
Software: Acq Knowledge 4.4, Biopac systems Inc) in-
strumented with a load cell (U2A, Hottinger Baldwin 
Messtechnik GmbH). The seat was adjusted to 100- and 
90- degrees hip and knee flection, respectively, the mo-
ment arm pad proximal to the ankle and the knee axis of 
rotation coincided with that of the apparatus. The partici-
pants were strapped across the hip, chest, and ankle of the 
right leg to minimize any joint movement. Adjustments 
were recorded to ensure consistent positioning between tri-
als. All participants were instructed to contract as hard and 
as rapidly as possible. After three submaximal warm-up 
contractions (~50%, 75%, and 90%), five MVCs were per-
formed with 60 seconds rest intervals. Peak torque, defined 
as the maximum voluntarily achieved value across the five 
MVCs, was used in the data analyses. RFDmax, defined as 
the maximum positive change of force over 10 ms intervals 
from initiation of contraction, as well as torque at 100 ms 
(from initiation of contraction) was extracted from the soft-
ware. The recordings had a sampling frequency of 1000 Hz 
and were smoothed with a moving average of 10 samplings 
before analyses.
Of the five MVCs, three were un-evoked and two were 
evoked utilizing the interpolated twitch technique (ITT).32 
The MVCs were performed in an alternating fashion, 
beginning and ending with an un-evoked contraction. The 
maximal voluntary activation level across the two attempts 
is presented. The peak torque of un-evoked MVCs controlled 
whether the evoked were in fact maximal contractions and 
contractions with torque prior to stimulus below 80% of peak 
torque were defined as submaximal and excluded from fur-
ther calculation of activation level (n = 6). Two self-adhesive 
surface electrodes (Veinoplus, 8  ×  13  cm, Oval shape, Ad 
Rem Technology) were positioned over the quadriceps of the 
right leg, one proximally and one distally, in a medial-lateral 
position to target as many muscle bellies as possible. An in-
tensity test was performed in rested state after the warm-up, 
to determine the stimulus output level for the ITT. The stim-
uli were given as 200 µs, 400 V single-imposed signals from 
a digitimer (Digitimer DS7AH HV Constant current stimu-
lator, Digitimer Ltd.), with successive increments until the 
evoked force amplitude was no larger than the previous. To 
ensure maximal evoked force, a 10% increase was added to 
the stimulus output, equating totally to 660-990  mA. Four 
“singlet” stimulations about 5  seconds apart and one dou-
ble-imposed stimulus at this output were given as familiar-
ization with the stimuli. The “doublet” was given as a 10 ms, 
100  Hz-stimulus (Digitimer DG2A Train/Delay Generator, 
Digitimer Ltd.) and was used during the evoked MVC.
The MVC was evoked at the peak of contraction, about 
0.5 seconds after initiation, and again as the quadriceps had 
relaxed and the force curve had returned to baseline. The 
percentage muscle activation level was determined with the 
following equation32:
where D is the difference between the voluntary and evoked 
force:
If submaximal voluntary force was achieved during the 
evoked contractions, the calculated muscle activation % was 
corrected by replacing Peak forceMVC in Equation (1) with the 
peak force across the un-evoked contractions. Test-retest mea-
surements revealed a CV of 9.7%, 7.1%, and 18.3% for peak 
torque, muscle activation level, and RFDmax, respectively.
2.5.3 | 1-repetition maximum
The participants completed 1-repetition maximum (1RM) in 
the squat followed by bench press (T-100G, Eleiko Sport). 






Mean forceMVC pre − stimulus
Peak forceMVC
�




D=Peak forceEvoked MVC−Mean forceMVC pre − stimulus
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sets with gradually increasing load (50-75-90% of maximal 
familiarization 1RM) and declining number of repetitions (8-
4-1). After 2 minutes rest, the first attempt was performed at 
95% of maximal familiarization 1RM. After each success-
ful attempt and 3-minute rest periods, the load was increased 
by 0.5%-5% (smallest increment 0.5 kg) until the participant 
reached voluntary failure. If the lift was unsuccessful, the 
load was decreased (0.5%-5%) for another attempt until 1RM 
was determined. The bench press 1RM test was performed 
in the same manner with a preceding 5-minute rest follow-
ing the squat RTF test (Figure 1). A Smith rack was used to 
prevent substantial change in the technique during the squats. 
Intra-individual control of equipment utilized (limited to 
weight lifting shoes, belt, wrist support, and knee sleeves), 
squat stance and bar position, bench press set up, and grip 
distance that the participants were accustomed to were noted 
and reproduced in the second trial. The CV for this test was 
2.3% for squats and 2.4% for bench press, and number of at-
tempts were 4-6 and 3-5, respectively.
2.5.4 | Muscular endurance and perceived 
exertion and pain
Repetitions to failure (RTF) were performed with 60% of 
maximal familiarization 1RM to ensure equal absolute load. 
The repetitions were counted out loud and a smart phone 
metronome application (Tap Metronome v1.2.1, Daniel 
Soper) was set to 15 BPM/4-seconds intervals to standard-
ize the repetitions. The technical requirements were (a) depth 
equating to hips below parallel and maintaining an upright 
torso position, and (b) a controlled change of direction and 
fully extended arms in the top position, for squats and bench 
press, respectively. If unable to complete a repetition within 
the two metronome signals, the following repetition had to 
be completed in time, otherwise the previous repetition was 
counted as the last. Failure was otherwise defined as failure 
to complete the repetition at all. The CV for this test was 
2.0% for squats and 2.4% for bench press.
From pilot testing and previous studies at 60% of 1RM,25,27 
it was expected that the participants would complete over 
20 repetitions in both the squat and bench press RTF test. 
Following repetition 10, the participants gave ratings of per-
ceived exertion from the 11-point Borg RPE C-10 scale (0 
[rest] to 10 [maximal exertion]). Perceived pain was rated 
from the 11-point NRS perceived pain scale (0 [no pain] to 
10 [worst imaginable pain]) immediately after the RTF tests.
2.6 | Plasma analysis
All samples were centrifuged for 10  minutes at 3000  rpm, 
1700  g, and 4°C (Heraeus Megafuge 16R, ThermoFisher 
Scientific, Thermo Electron LED GmbH) before transferring 
plasma to two 1.5 mL micro tubes (MCT-150-C, Axygen, Inc 
for storage at −80°C until further preparation and analyses.
Samples were analyzed in duplicate with reverse phase 
LC-MS (Dionex Ultimate HPLC 3000 system; Agilent TOF 
6230, positive electrospray ionization [ESI]), based on the 
method used by Chen et al.33 We were not able to separate 
paraxanthine and theophylline; hence, all paraxanthine anal-
yses included small contributions (~4% of total caffeine me-
tabolites concentration) from theophylline.34 Individually 
prepared quality control samples at three concentration levels 
and a blank sample were included in each run of the plasma 
analyses. Limit of detection (LOD) and limit of quantifica-
tion (LOQ) were determined based on signal-noise ratio to 
be <0.008 μg·mL−1 and <0.05 µg·mL−1, respectively. In all 
samples where the analytes were non-detected or estimated 
<LOQ, values were substituted with worst case scenarios 
equal to LOD and LOQ, respectively, that is biased high, 
to enable statistical analyses comparing baseline to 60- and 
270 minutes.
2.7 | Statistical analyses
The sample size was calculated using a priori t tests for 
paired samples to ensure sufficient statistical power in 
the main analyses (G*Power version 3.1, Heinrich-Heine 
University).35 With α-level set at 0.05 for the main outcomes 
and a 1-β error probability of 0.8, we used the mean and 
SD from Goldstein et al27 to calculate the sample size. Ten 
participants were needed to detect a true mean difference in 
1RM strength of 0.8  kg (1.54% difference). Due to an ex-
pected drop out of 25%, we aimed to recruit a minimum of 15 
subjects for the present study.
All variables’ distributions were tested with the Shapiro-
Wilks normality test and assessing skewness, kurtosis, and 
histograms. Paired sample t tests and Wilcoxon signed-rank 
tests were performed on paired differences with Gaussian 
and non-Gaussian distribution, respectively, and P  <  .05 
was considered statistically significant. Values are given as 
mean ± SD and median (confidence interval) for parametric 
and non-parametric tests, respectively. To assess “practical” 
significance, Hedge's g values were calculated with weighted 
and pooled SD’s and adjustment for samples n < 50. Effect 
size cutoffs were defined as <0.25, 0.25-0.5, 0.5-1.0, and 
>1.0 for trivial, small, moderate, and large effect sizes, re-
spectively.36 Values are given as mean ± SD and as median 
(confidence interval) for parametric and non-parametric tests, 
respectively. The ergogenic effects of caffeine dependent of 
order of trials and caffeine identification were assessed with 
unpaired t tests. Pearson r correlation was assessed between 
habitual caffeine intakes and delta caffeine effects. CV for the 
main outcomes was calculated from the two familiarizations 
2122 |   NORUM et al.
and the last familiarization and the placebo trial, and the 
largest was consistently chosen throughout. Statistical anal-
yses were performed using GraphPad Prism 7.0 (GraphPad 
Software, Inc).
3 |  RESULTS
There were no significant differences in the macronu-
trient intake prior to each of the trials (carbohydrate 
[P =  .39], fat [P =  .62], protein [P =  .59]) and overall 
energy intake (P = .77), or in withdrawal symptoms (all 
P  >  .16) or BRUMS mood score on commencement of 
either trials (all P > .42). On the post-trial question about 
which treatment the participants thought they received, 
seven participants (44%) correctly guessed the treatment 
order (ie, correctly guessed both conditions), stating rest-
lessness, heart palpitations, and or increased energy and 
motivation as reasons for guessing caffeine. However, 
10 participants (66%) total correctly identified caffeine 
independent of identifying placebo. No differences were 
observed in the effects of caffeine between the identifiers 
and non-identifiers of the caffeine condition (all P > .20, 
see Appendix Table  A1) or by the order of trials (all 
P >  .13, see Appendix Table A2). All performance and 
plasma caffeine concentration data are shown in Tables 2 
and 3, respectively.
3.1 | Countermovement jump
The mean CMJ jump height, maximal power, and maximal 
force across the two trials were 33 ± 2 cm, 2893 ± 74 W, 
and 1570 ± 26 N, respectively. Jump height and peak power 
increased by 2.3  ±  1.1  cm (7.6  ±  4.0%) and 105  ±  63  W 
(3.8 ± 2.2%), respectively (Table 2; Figure 3). No difference 
was observed in peak force.
3.2 | Maximal isometric strength, rate of 
force development, and muscle activation level
The mean peak torque, RFDmax, and activation level across 
the two trials were 177 ± 6 Nm, 19 ± 1 Nm·10 ms−1, and 
86  ±  1% muscle activation, respectively. Caffeine signifi-
cantly increased peak torque of the knee extensors by 11 Nm 
(CI: 2-18 Nm), corresponding to 4.6 ± 7.3%, compared to 
placebo (Figure  2). No difference was observed with caf-
feine on muscle activation level (−2 ± 4%, n = 9, Figure 2), 
RFDmax (1.1 ± 4.9 Nm·10 ms−1 [9.2 ± 26.5%], Figure 3), or 
torque at 100 ms (−2.9 ± 26.2 Nm, Table 2). Six participants, 
in one or both of the trials, had a substantially lower force 
output during the evoked MVC than the unevoked MVC. The 
force output during the evoked MVC was 26%-78% of the 
peak torque contraction in these six participants, whom were 
excluded from the statistical analyses.
T A B L E  2  The effect of caffeine on performance outcomes
Performance outcomes Placebo Caffeine
Mean of 
Δ ± SD 95% CI P-value
Effect 
size- Magnitude
CMJ jump height (cm) 32.0 ± 4.7 34.3 ± 4.5 2.3 ± 1.1 1.7, 2.9 <.001 0.44 - Small
CMJ peak power (W) 2840 ± 430 2946 ± 430 105 ± 63 71, 140 <.0001 0.21 - Trivial
CMJ peak force (N) 1550 ± 247 1588 ± 247 37 ± 96 −16, 91 .16 0.13 - Trivial
MVC peak torque (Nm) 173 ± 29 181 ± 31 11a 2, 18 .02 0.23 - Trivial
MVC activation level (%) [n = 9] 87 ± 5 85 ± 5 −2 ± 4 −5, 1 .16 −0.35 - Small
MVC RFDmax (Nm
.10 ms−1) 15 ± 5 17 ± 6 2 ± 5 −0.5, 4.5 .10 0.34 - Small
MVC Torque100ms (Nm) 75 ± 24 72 ± 29 −3 ± 26 −17, 12 .67 −0.09 - Trivial
1RM Squat (kg) 96 ± 14 100 ± 13 4 ± 1 3, 5 <.001 0.27 - Small
RTF Squat (repetitions) 39 ± 17 45 ± 17 5.8 ± 6.2 2, 9 .003 0.27 - Small
RPE Squat rep 10 6 ± 1 6 ± 1 −1a −1, 1 .67 0.05 - Trivial
PP Post-squat 8 ± 1 9 ± 2 0a −1, 0 .60 0.07 - Trivial
1RM Bench press (kg) 66 ± 10 68 ± 11 2 ± 1 2, 3 <.001 0.18 - Trivial
RTF Bench press (repetitions) 21 ± 6 23 ± 6 2 ± 3 0, 3 .01 0.27 - Small
RPE Bench press rep 10 7 ± 1 7 ± 1 0a −1, 1 >.99 0.09 - Trivial
PP Post-bench press 8 ± 2 7 ± 1 0a −1, 0 .14 0.27 - Small
Note: Values are presented as mean ± SD or mediana and 95% confidence intervals.
Abbreviations: 1RM, one repletion maximum; CI, 95% confidence interval; CMJ, countermovement jump; Δ, difference between trials; MVC, maximal voluntary 
contractions; PP, perceived pain; RPE, rating of perceived exertion; RTF, repetitions to failure.
aNon-Gaussian distributed paired differences tested with Wilcoxon paired rank test. 
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3.3 | 1-repetition maximum
The mean absolute weight lifted across the two trials 
was 98.4 ± 2.4 kg and 66.6 ± 1.5 kg for squat and bench 
press, respectively. Compared to placebo, caffeine inges-
tion increased 1RM in the squat and in the bench press by 
4.1 ± 1.4 kg (4.5 ± 1.9%) and by 2.2 ± 1.0 kg (3.3 ± 1.4%) 
(see Table 2 and Figure 2).
3.4 | Muscular endurance and perceived 
effort and pain
The mean absolute weight lifted during the RTF test (60% 
of familiarization 1RM) was 58  ±  8  kg and 39  ±  6  kg in 
squats and bench press, respectively. Caffeine significantly 
increased squat RTF by 5.8 ± 6.2 repetitions (15.9 ± 17.9%) 
and bench press RTF by 1.8 ± 2.5 repetitions (9.8 ± 13.6%), 
compared to placebo (Table 2; Figure 4). No differences be-
tween trials were found in intra-set RPE at repetition 10 or in 
at-failure perceived pain (Table 2).
3.5 | Plasma caffeine concentration
Upon arrival on both trial days, plasma caffeine concentra-
tions were negligible, that is, not detected or <LOQ in all 
participants except two in the placebo trial and one in the 
caffeine trial (all 0.4 μg·mL−1). At baseline, theobromine 
was significantly higher in the placebo compared to the 
caffeine trial (P = .03); however, 8 and 9 of the individual 
values, respectively, were below LOQ. Due to the choco-
late protein powder administered all participants, theobro-
mine was significantly increased from baseline to 60 and 
T A B L E  3  The effect of caffeine on plasma concentrations
Analyte
Caffeine Placebo
Baseline 60 min 270 min Baseline 60 min 270 min
Caffeine (μg·mL−1) 0.0 ± 0.1 3.6 ± 0.8a,c 3.1 ± 0.9a,b,c 0.1 ± 0.2 0.1 ± 0.1 0.0 ± 0.0
Paraxanthine (μg·mL−1) 0.1 ± 0.1 0.8 ± 0.4a,c 1.7 ± 0.8a,b,c 0.1 ± 0.2 0.1 ± 0.1 0.2 ± 0.2
Theobromine (μg·mL−1) 0.0 ± 0.0 0.5 ± 0.1a 0.7 ± 0.1a,b 0.2 ± 0.3c 0.6 ± 0.4a 0.8 ± 0.4a 
TC (μg·mL−1) 0.2 ± 0.3 4.9 ± 0.9a,c 5.6 ± 1.0a,b,c 0.4 ± 0.6c 0.8 ± 0.6 1.0 ± 0.6a 
Note: All baseline and placebo mean values are based on several substituted values for non-detected and non-quantifiable measurements equal to limit of detection 
and limit of quantification, respectively, and thus, should be interpreted with caution. Paraxanthine concentrations include a small contribution of the metabolite 
theophylline.
Values are presented as mean ± SD.
Abbreviation: TC, total concentration of metabolites.
aDifferent from within condition baseline (P < .05). 
bDifferent from within condition 60 min (P < .05). 
cDifferent from between condition corresponding time-point (P < .05). 
F I G U R E  2  Effect of caffeine on 
maximal strength and activation level. 
Individual results (dotted lines) and 
mean ± CI (solid lines) are presented for (A) 
squats; and (B) bench press 1RM; (C) MVC 
peak torque and (D) MVC activation level 
of the knee extensors (n = 9). *Significantly 
different from placebo (P < .05). CI, 
95% confidence interval; MVC, maximal 
isometric voluntary contraction
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270 minutes during both trials (all P < .01) with no differ-
ences between trials (P > .05). No other analyte increased 
from baseline during the placebo trial (all P > .05). In the 
caffeine trial, plasma caffeine concentration increased to 
3.6  ±  0.8 (P  <  .001) and 3.1  ±  0.9  µg·mL−1 (P  <  .001) 
60 and 270  minutes following ingestion, respectively, 
confirming intention to treat (Table 3). Paraxanthine and 
total metabolite concentration significantly increased from 
baseline to 60 minutes and 270 minutes following caffeine 
ingestion (all P > .001, Table 3).
3.6 | Habituation
The habitual caffeine intake was 341  ±  184  mg·d−1, cor-
responding to 5.4  ±  2.9  mg·kg−1, while the administered 
dose of 4  mg·kg−1 equated to 254  ±  20  mg. The partici-
pants were moderate to high caffeine consumers (n catego-
rized as low, moderate, high: 2, 5, 8, respectively). Only 
the effect of caffeine on muscular endurance was signifi-
cantly correlated with the habitual intakes (Pearson r = .52, 
P = .045 and r = .58, P = .024 for squat and bench press 
RTF, respectively).
4 |  DISCUSSION
This study investigated the acute effects of 4 mg·kg−1 caf-
feine ingestion on maximal isometric and dynamic mus-
cle strength, power, activation level, RFD, and muscular 
endurance in resistance-trained females during the early 
follicular phase. There were several notable findings in 
the present study. Caffeine ingestion increased dynamic 
strength measured as 1RM in squat and bench press and 
isometric knee extension torque, leg muscle power and 
jump height in CMJ, and improved both squat and bench 
press muscular endurance measured as repetitions per-
formed until failure at 60% of 1RM. However, no effect of 
caffeine was observed on RFD, muscle activation, or affect 
perceived exertion and pain.
In this study, caffeine increased maximal upper body 
strength, which is in agreement with Grgic et al's recent me-
ta-analysis,4 as well as the study by Goldstein et al27 who found 
increased bench press 1RM performance (1.5%) in 15 resis-
tance-trained females. It is suggested that smaller upper body 
muscles are less affected by caffeine than larger lower body 
muscles,6 which has been implied by studies on for example 
elbow flexors, not showing effects on maximal strength with 
F I G U R E  3  Effect of caffeine on rate 
of force development and countermovement 
jumps. Individual results (dotted lines) and 
mean ± CI (solid lines) are presented for 
(A) RFD max during MVC of the knee 
extensors; (B) CMJ jump height; (C) CMJ 
Peak force; and (D) CMJ Peak power. 
*Significantly different from placebo 
(P < .05). CI, 95% confidence interval; 
CMJ, countermovement jump; MVC, 
maximal isometric voluntary contraction; 
RFD, rate of force development
F I G U R E  4  Effect of caffeine on muscular endurance. Individual results (dotted lines) and mean ± CI (solid lines) are presented for (A) squats 
and (B) bench press repetitions to failure at 60% of familiarization-1RM. *Significantly different from placebo (P < .05). CI, 95% confidence 
interval
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caffeine.23 Moreover, the positive associations seen between 
strength and muscle activation with caffeine suggests that mus-
cles with high baseline activation level, such as upper body 
muscles like the elbow flexors, would likely be less affected 
by caffeine, that is,there is less room to improve.6 However, 
in studies examining multi-joint upper body exercises, there 
seems to be an overall trend that caffeine has positive effects on 
strength.4 This discrepancy might be explained by more mus-
cle mass being recruited as compared to single joint arm exer-
cises, including several muscles with varying activation levels, 
which might potentiate the effect of caffeine. The present re-
sults support that multi-joint upper body strength is indeed af-
fected by caffeine, although possibly still less than lower body 
strength (3.3% [ES:0.20] vs 4.5% [ES: 0.25] increase in bench 
press and squat 1RM, respectively).
A novel finding of this study was that a dose of only 
4 mg·kg−1 caffeine induced a similar or even greater effect 
on bench press 1RM than a dose of 6 mg·kg−1 in the study by 
Goldstein et al27 (+3.3% vs +1.5%, respectively). The slight 
difference in performance between our study and Goldstein 
et al27 may partly be explained by severity of adverse events 
occurring during the caffeine trial. Three participants felt 
“shaky” and the remaining participants reported no adverse 
events in the present study, as opposed to three participants 
“exhibiting intense emotional responses” in the study by 
Goldstein et al,27 who reported habitual caffeine intakes of 
only 0-41 mg·d−1. The difference in side effects may be ex-
plained by the lower acute dose of caffeine (4 vs 6 mg·kg−1) 
and possibly due to higher habitual caffeine intakes in the 
present trial (341 ± 184 mg·d−1).
Even though habitual caffeine intake may influence the 
prevalence of adverse events, it might not affect exercise per-
formance. A study,37 although on endurance performance, 
found that acutely ingesting 6 mg·kg−1 caffeine increased 
performance irrespective of whether the daily habitual in-
take was low (0.8  mg·kg−1), moderate (1.9  mg·kg−1), or 
high (4.6 mg·kg−1) and that habituation was not correlated 
with performance. This is in line with the results of the 
present study, and in addition, and contrary to the above 
study, we report the same for participants habitually con-
suming more than the acute dose administered (4 mg·kg−1 
vs 5.4  mg·kg−1·d−1, respectively). Importantly, habitual 
caffeine may be consumed in small doses over the day, so 
an acute dose of 4 mg·kg−1 may induce higher peak plasma 
concentration levels than many habitual consumers will 
experience by administering 5.4  mg·kg−1·d−1 daily. This 
raises the question if the use of high doses is necessary to 
achieve an equally or potentially better ergogenic effect as 
seen in the example with Goldstein et al's study.27 Thus, 
future research should explore optimal caffeine dosage in 
relation to habituation.
Squat 1RM increased (+4.5%) significantly in this study, 
as opposed to Grgic et al's meta-analysis,4 who observed no 
overall effect on lower body maximal strength. However, 
very few studies have been conducted examining dynamic, 
multi-joint maximal strength in females, indicated by only 
three included in the above meta-analysis from 2018.25,27,38 
Two of the three studies investigated lower body maximal 
strength, in which one observed an effect of caffeine and the 
other a trend of increased performance.25,38 Thus, one could 
speculate whether females could have a greater effect of caf-
feine on lower body dynamic strength compared to males. 
Furthermore, Grgic et al4 discuss that the included studies did 
not report the reliability of their strength tests. In the present 
study, we report a low CV (2.3%) for the squat 1RM, which 
could partly explain why we were able to detect an effect of 
caffeine.
Although no sex differences have been reported on the 
ergogenic effects of caffeine on exercise performance,2 only 
two studies,15,16 to our knowledge, have investigated caf-
feine's effects on sex differences with strength-power modal-
ities, showing similar effects (or lack of effects) of caffeine 
in both males and females.15,16 As previously mentioned, 
fluctuating hormone levels with the phases of the menstrual 
cycles can alter caffeine metabolization speeds,12 as well as 
neuromuscular function,20 and ultimately the ergogenic ef-
fects of caffeine. As an example, a recently published study 
showed that half squat velocity was increased by 1.4%, 5%, 
and 5.3% in the early follicular, late follicular, and mid-luteal 
phase, respectively.17 Thus, ensuring caffeine research in fe-
males is conducted during the same menstrual cycle phase 
is important and furthermore, which phase could potentially 
affect the effect size. Moreover, only one15 of the two stud-
ies comparing effects of caffeine on strength performance 
between the sexes controlled for menstruation cycle phase. 
Therefore, further research is still warranted to establish 
whether sex differences in ergogenic effect of caffeine on 
maximal strength occur.
The effect of caffeine on maximal isometric strength ob-
served in this study is in agreement with Warren et al's me-
ta-analysis findings,6 who found caffeine to have a moderate 
effect on isometric knee extensor strength. On the other hand, 
Ali et al14 found no effects of 6 mg·kg−1 caffeine on knee ex-
tensor isometric strength in women. However, their protocol 
measured maximal muscle strength between fatiguing blocks 
of sprints and consequently, might have masked a caffeine-in-
duced effect on maximal strength.
No effect of caffeine on voluntary muscle activation 
of the knee extensors was observed in the present study. 
Previous studies such as Behrens et al22 demonstrated that 
strength enhancements by caffeine are associated with in-
creased voluntary activation, and the meta-analysis by 
Warren et al6 showed that caffeine has an moderate effect 
on voluntary muscle activation. On the other hand, Meyers 
& Cafarelli39 found no effect of caffeine on muscle activa-
tion level after ingesting 6 mg·kg−1 of caffeine. The initial 
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activation level in Meyers & Cafarelli's39 study was ~94% 
compared to 70%-80% in the study by Behrens et al,22 
which may suggest that baseline muscle activation level 
may affect the results, that is, the higher baseline level the 
less room to improve. In the present study, the participants 
had a muscle activation level of 85%-87%, which could 
partly explain why we did not detect any effects of caffeine. 
Six participants (excluded from analysis of activation level) 
found it especially difficult to maximally contract during 
the ITT compared to the un-evoked contractions, indepen-
dent of treatment. These participants’ maximal force output 
when knowing they would be stimulated was ~25%-75% 
lower than the intra-trial peak force, although they reported 
that they felt they were contracting as forcefully as possi-
ble. Thus, there may be a psychological factor (ie, being 
afraid of the electrical stimuli) inhibiting the voluntary con-
traction when knowing electrical stimuli would be given. 
Potentially, this might be overcome with further familiar-
izations to increase the reliability of the test, that is, more 
than two as in the present study. However, this is a well-
known negative effect of stimulus anticipation in the ITT 
method.40
The main mechanism by which caffeine induces ergo-
genic effects on muscular strength and power is thought to in-
volve supra-spinally-driven increases in muscle activation.14 
Surprisingly, we did not observe any difference between 
conditions in muscle activation level or RFDmax, despite 
demonstrating effects in 1RM strength, isometric strength, 
and power. However, the high CV revealed especially for 
RFDmax (18.3%) in the present study increases the risk of 
a type II error as the statistical power might have been too 
low to detect a possible effect. Nevertheless, this is a com-
mon challenge and even higher CVs than demonstrated in 
this study are typically reported for RFD in the literature.41 
Furthermore, RFD is closer associated to the rate of mus-
cle activation (RMA) rather than just muscle activation per 
se, as demonstrated by a recent study showing that the pre-
ceding effective motor neuron drive to the muscle influences 
changes in RFD.42 Unfortunately, we did not measure RMA 
in the present study. It could be speculated that the influence 
of caffeine on changes in RMA is not as profound as with 
other strength-power measures.
In parallel to the observed effect on muscle strength but 
in contrast to the lacking effect on RFD, caffeine ingestion 
improved performance and power measures in the CMJ; the 
participants jumped 2.3 cm higher with caffeine than in the 
placebo trial. In line with previous divergent results of caf-
feine effects on maximal strength, the acute effects of caf-
feine ingestion on strength-power performance and RFD are 
inconsistent, but most studies show significant increased 
lower body power during countermovement jumps.4 In a 
subgroup meta-analysis,4 training status indicated a signifi-
cant effect for athletes, but not for non-athletes. Although our 
participants were not athletes, one could speculate that the 
training status of our participants might have contributed to 
the positive effect of caffeine. Altogether, the evidence sug-
gests that caffeine acutely improves power, which is in line 
with our results.
Finally, 4  mg·kg−1 caffeine ingestion also significantly 
increased muscular endurance in both lower (~16%) and 
upper body (~10%,) exercises in this study. These results 
are in agreement with Duncan et al,43 who found 5 mg·kg−1 
caffeine to increase the number of bench press repetitions to 
failure (60% of 1RM) in men. On the other hand, these results 
are in disagreement with other studies in females who did not 
find any effects on muscular endurance.16,25,27 However, hor-
mone concentration and hormone contraceptive use were not 
controlled for16,25,27 and one did not report familiarization,16 
while the other two only performed one familiarization ses-
sion.25,27 In the present study, the participants who performed 
three familiarization sessions were mainly participants with 
CV > 9% in the muscular endurance tests. Hence, there could 
have been a masking of the caffeine effect in the studies with 
only one or no familiarization, due to continued learning ef-
fect in both trials.
Caffeine reducing pain perception and RPE is a possible 
mechanism for increased performance,21 and, as mentioned 
in the introduction, in a 2005 meta-analysis, Doherty et al,24 
observed that a ~5% reduction in RPE during, as opposed 
to at-failure, explained about a third of the variance in ex-
haustive work performance between caffeine and placebo. 
However, and albeit the analgesic effects might be easier to 
observe when assessed intra-set compared to at-failure (due 
to an assumed greater relative difference in motor output be-
tween trials when caffeine increases number of repetitions 
performed), no difference in intra-set RPE was observed be-
tween the caffeine and placebo trials in the present study. The 
fact that RPE was assessed only one time during the set and 
that a lower dose was used than most of the included studies 
in the meta-analysis (4 vs 6 mg·kg−1) could explain why no 
difference in intra-set exertion was observed.
Total caffeine concentration and the individual metabo-
lites were significantly higher at 270  minutes as compared 
to 60 minutes after ingestion, whereas caffeine tended to be 
lower. Theophylline and paraxanthine can contribute to the 
pharmacological effect on the central nervous system as these 
also inhibit the adenosine A1 and A2 receptors.
44 Theophylline 
is considered to be three to five times more potent than caf-
feine, and paraxanthine may be as potent as caffeine.44 Thus, 
we can expect that the participants in the present study had 
similar effects of caffeine throughout the test protocol (60-
270 minutes following ingestion), and we did indeed observe 
significant effects both on the first (CMJ), as well as the last 
(bench press RTF) test of the protocol.
Controlling for hormone concentrations in the way which 
was used in the present study is cost- and time-efficient, 
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when assuming the participants are having no health is-
sues that would affect their hormones around the menstrual 
cycle. To our knowledge, this is only the second study on 
the effects of caffeine on strength performance to control 
for oscillations in reproductive hormones in this way.15 
However, we did not confirm the hormone concentrations 
in blood samples, which would be a strength of future stud-
ies. Recently, as mentioned, the first study on the effect 
of caffeine on half squat velocity during three phases of 
menstrual cycle was published.17 Nevertheless, we recom-
mend that further studies compare the effects of caffeine on 
female strength and power performance between the men-
strual cycle phases to establish the interaction of female 
reproductive hormones on the ergogenity of caffeine. This 
is warranted to further optimize personalized recommen-
dations for caffeine use in female athletes and will inform 
future research on caffeine in females. Another strength of 
this study is the blinding efficacy check, a potential bias 
in the caffeine literature, as recently discussed by Painelli 
et al45 and Pickering and Grgic.46 Although 66% partici-
pants correctly guessed when they ingested caffeine, no 
difference in performance was observed between these and 
those that guessed incorrectly in the present study. Thus, 
the performance increments observed in the caffeine trial 
do not seem to be due to the placebo effect.
A limitation of this study is a skewed counterbalance of 
treatment order arising due to dropout after randomization. 
Consequently, ten participants received placebo and five 
participants received caffeine in the first trial. However, we 
could not detect an effect of treatment order. All participants 
had an effect of caffeine irrespective of order of trial on CMJ 
jump height and power and on maximal strength, and fur-
thermore, 12 of the 15 participants performed better with 
caffeine in the muscular endurance and isometric strength 
tests. Nevertheless, the low statistical power in the analyses 
of treatment order in the latter outcomes increases the risk of 
type II error.
In conclusion, ingestion of 4 mg·kg−1 caffeine 60 minutes 
prior to tests improved maximal strength and power in highly 
resistance-trained females during the early follicular phase of 
menstruation. The caffeine supplementation also increased 
muscular endurance in both upper and lower body exercises 
without differences in perceived exertion or pain. Furthermore, 
very few adverse events were reported, and caffeine-induced 
ergogenic effects were observed although the participants ha-
bitually were consuming in excess of the acute dose.
4.1 | Perspectives
These findings of 3%-5% improvement on maximal 
strength and power could potentially be relevant to female 
strength and power athletes, where the margins between top 
placements in competition can be small. However, within-
individual differences in performance need to be taken into 
account and the acute effects of caffeine may be smaller in a 
competitive context due to increased arousal. Performance 
effects of caffeine during the different menstrual cycle 
phases should be investigated further. Establishing whether 
menstrual cycle phase affects the ergogenity of caffeine al-
lows optimization of personalized recommendations and 
will inform future caffeine research. Furthermore, further 
examination of the potential sex differences in the ergo-
genic effect of caffeine on strength and power is warranted. 
At the time being, such research should take into account 
the effects of menstrual cycle phase. Lastly, the long-term 
effects of chronic caffeine supplementation on resistance 
exercise adaptations have not been investigated and are thus 
warranted.
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